Anal Cancer Market Size (2024 - 2029)

Anal Cancer Market Analysis

The Anal Cancer Market size is estimated at USD 0.91 billion in 2024, and is expected to reach USD 1.26 billion by 2029, growing at a CAGR of 6.60% during the forecast period (2024-2029).

The COVID-19 pandemic influenced the anal cancer market through supply chain disruptions that hindered the manufacture and distribution of medical products required for anal cancer treatment. Due to the global pandemic, the healthcare staff put more effort into combating the infections, and other medical procedures and cancer screening were declined. For instance, in August 2023, an article published in the eClinical Medicine Journal estimated that COVID-19-related screening resulted in the loss of around 7.4 million lower fecal screenings in colorectal cancer during the beginning of the pandemic. Thus, the decline in anal cancer screening affected the diagnosis and treatment of anal cancer, hence impacted the market during the pandemic. There was a significant risk of anal cancer in individuals with COVID-19 infection and other cancers. Thus, due to the high risk of anal cancer development and progression with COVID-19 infection and other comorbidities contributed to the market growth.

Various factors, such as the incidence of anal cancer, the increase in the prevalence of sexually transmitted diseases and anal cancer, and the rise in research and development activities, will lead to market growth during the forecast period.

The increase in the incidence of anal cancer and the prevalence of sexually transmitted infections and anal cancer is the primary factor influencing the market growth. Anal cancer is caused by the human papillomavirus due to skin-to-skin contact of the genital organs, resulting in a sexually transmitted disease. For instance, Cancer Research UK published statistics reported that anal cancer incidence rates are projected to grow by 14% in the United Kingdom between 2023-2025 and 2038-2040, and there are approximately 2,400 new cases of anal cancer every year in the United Kingdom by 2038-2040. Additionally, anal cancer is predominantly found in females as compared with males. Thus, the growing incidence rate of anal cancer is a significant factor boosting the market growth over the forecast period.

Moreover, the increase in research and development activities for the production of effective treatments to treat anal cancer is contributing significantly to the market growth. For instance, in July 2022, the Anal Cancer Foundation published an Anal Cancer high-grade squamous intraepithelial lesion (HSIL) Outcomes Research (ANCHOR) study in the New England Journal of Medicine, represented that early detection and treatment of anal HSIL (anal precancer) can decrease disease progression by 57%. Additionally, the study found that the incidence rate of anal cancer was higher in the patients infected with the human immune-deficiency virus (HIV). Moreover, partnerships of research institutes promote the treatment development of anal cancer. For instance, in September 2023, the University of Cincinnati Cancer Center Research established a partnership with Ride Cincinnati (an organization involved in cancer research and care), which raised funding of USD 4 million for the treatment of patients with anal cancer and improving the quality of life of patients. Thus, increased research activities to determine the causes and effective treatments contributed to the market growth.

Hence, the increase in the prevalence of sexually transmitted infections will contribute to the rise in anal cancer cases, and the increase in research and development activities with significant funding are the major factors driving the market growth. However, the side effects of chemotherapy and the high cost of treatments may affect the market growth of anal cancer over the forecast period.

Anal Cancer Industry Segmentation

According to the scope, anal cancer is an abnormal growth of cells in or around the anus or anal canal.

The anal cancer market is segmented by cancer type (carcinoma in situ, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, and other cancer types), treatment type (chemotherapy, surgery, radiation therapy, and immunotherapy), end-users (hospitals and clinics, research and academic institutes, and other end-users) and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.

The report offers a value of USD for the above segments.